The outcome of the presidential election sent pharmaceutical and biotechnology stocks rising, but at least one analyst said the "enthusiasm could be short-lived" because the issues that faced the industries before the election still remain. But others see President George W. Bush's re-election as making it less likely the government will impose price controls. Scientists anticipate conflict between individual states and the federal government over a variety of issues during Bush's second term. Carl Feldbaum, president of the Biotechnology Industry Organization, argues "the big issues for biotech are who the new president will appoint to key positions such as the FDA commissioner and other agencies if vacancies occur."
Published in Brief: